Health Care · Surgical & Medical Instruments & Apparatus

BSX Boston Scientific SEC Filings & Insider Trading Activity 2026

company
CIK 88572599 filings
S&P 500

BSX at a glance

Boston Scientific (BSX, SEC CIK 885725) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Boston Scientific (BSX) reported revenue of $20.1 billion (up 19.9% from FY2024) and net income of $2.9 billion. Diluted EPS was $1.94.
  • As of September 30, 2026, 45 institutional investment managers tracked by SignalX reported holding Boston Scientific (BSX) shares worth $24.9 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Morano Susan E on August 25, 2026 of 2,040 shares at $49.22 per share.
  • In the last 90 days, BSX insiders reported 1 open-market purchase ($100K) and 0 open-market sales ($0) on Form 4, a net purchase of $100K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$20.1B
+19.9% vs prior year
Insiders · 90 days
1 buy · 0 sells
Net +$100K
13F holders
45 funds
$24.9B · −1 vs prior quarter
Latest 8-K
Nov 20, 2026
Item 8.01 · Item 1.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Medical devices portfolio across Endoscopy, Urology, Neuromodulation, MedSurg, and Cardiovascular segments
  • Cardiovascular strategic shift: Discontinued ACURATE Neo2/Prime Aortic Valve sales globally, ceased pursuit of FDA and other approvals in 2025
  • Notable new acquisitions emphasized: Axonics (Urology), Silk Road Medical and Intera (Cardiovascular), Braun vacuum therapy (Endoscopy)
  • Quantitative highlight: Net sales increased 19.9% to $20.1B in 2025, R&D spend rose 27% to $2.05B, SG&A expenses up 15%
  • Unusual fact: $194 million litigation charge in 2025 due to resolution of legacy IP claim tied to acquisition

Risk Factors

  • Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024
  • Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M
  • No restructuring charge exclusion remaining after using $500M limit; litigation exclusion $1.160B remaining under credit agreement
  • Qualified Acquisition leverage step-down schedule triggered by $1B+ Axonics purchase with elevated ratios through seven quarters
  • Current debt $299M sharply down from $1.778B in 2024, reflecting liability management or refinancing activities

Management Discussion & Analysis

  • No revenue, profitability, segment, or cash flow data disclosed in provided MD&A section
  • Management implementing new global ERP affecting internal controls, phased rollout began August 2025 in EMEA
  • Senior HR officer initiated a Rule 10b5-1 trading plan for sale of 14,912 shares, effective through Dec 31, 2026
  • No forward-looking guidance, risks, or financial outlook information included in the disclosed text

AI summary of the BSX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $5.138B, up 1.5% YoY from $5.065B
  • Gross margin 66.7% vs 69.9% YoY; adjusted net income $1.063B vs $1.124B
  • Best segment Cardiovascular, $3.406B, up 1.9%; worst Urology, down 3.2%
  • Operating cash flow $2.870B for nine months vs $3.170B; $2.000B share repurchase
  • Headwinds: cybersecurity disruption, Electrophysiology competition, WATCHMAN™ market deceleration, tariff uncertainty

Risk Factors

  • Cybersecurity incident risk: August 26, 2026 incident could disrupt operations and financial results
  • Penumbra acquisition regulatory risk: FTC issued a Second Request on March 16, 2026
  • Spinal cord stimulator litigation risk: MDL consolidated federal product-liability cases on June 5, 2026
  • Supply-chain restructuring risk: 2026 plan transfers production lines through 2029
  • Commercial paper liquidity risk: $1.029 billion outstanding, reducing available capacity to $1.721 billion

AI summary of the BSX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 20, 2026Full analysis →

Item 8.01: Other Events

  • November 19, 2026 press release announces the material event described in the 8-K
  • Exhibit 99.1 contains the substantive details investors need to assess the event’s impact on Boston Scientific

Item 1.01: Entry into a Material Definitive Agreement

  • $3.0B USD notes and €4.25B euro notes priced November 19, 2026, with expected closing December 1, 2026
  • Fixed-rate coupons range from 5.375% to 5.875% on USD notes, maturing 2029-2036

Item EX-99.1: Item EX-99.1

  • $3.0B USD and €4.25B euro senior-note offerings priced, substantially expanding debt funding
  • Coupon structure: USD notes 5.375%-5.875% due 2029-2036, euro notes 3.875%-5.125% due 2028-2046
Filed Nov 17, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • 2027 annual bonus plan approved for executives and eligible employees, with payouts tied to global sales and adjusted EPS
  • Companywide bonus distribution 0%-150%, plus individual performance modifiers up to 150%

Item 8.01: Other Events

  • David S. Wichmann becomes Lead Independent Director effective January 1, 2027
  • Edward J. Ludwig relinquishes the lead role after serving since 2016, remaining on the Board
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 net sales $5.138B, up 1.5%, but GAAP EPS fell to $0.40 from $0.51
  • Adjusted EPS $0.73, down from $0.75, with litigation charges $81M and restructuring charges $63M

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Investors should review Exhibit 99.1 for revenue, earnings, guidance and business-segment performance 乐友

AI summaries of BSX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BSX

Don't miss the next BSX filing

  • Alerts as it files. A push when BSX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BSX, by share count.
  • Ask anything. An AI agent that reads every BSX filing and answers with sources.

BSX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Mahoney Michael FGNov 4, 2026-
Mahoney Michael FGNov 4, 2026-
O'Sullivan MiriamMNov 1, 2026-
O'Sullivan MiriamMNov 1, 2026-
O'Sullivan MiriamFNov 1, 2026$41.98
O'Connor Padraig AndrewMSep 2, 2026-
O'Connor Padraig AndrewMSep 2, 2026-
O'Connor Padraig AndrewFSep 2, 2026$48.37

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$16.7B$20.1B
Gross Profit-$11.5B$13.9B
Operating Income-$2.6B$3.6B
Net Income-$1.9B$2.9B
Gross Margin-68.6%69.0%
Op. Margin-15.5%18.0%
Net Margin-11.1%14.4%
Balance Sheet
Total Assets$35.1B$39.4B$43.7B
Equity$19.3B$21.8B$24.2B
ROE-8.5%12.0%
Per Share
EPS-$1.25$1.94
Cash Flow
Operating CF-$3.4B$4.5B
CapEx-$790.0M$876.0M

Source: XBRL data in Boston Scientific (BSX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BSX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BSX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202645$24.90B
Q2 202646$25.31B
Q1 202651$39.43B
Q4 202552$61.15B
Q3 202551$67.84B
Q2 202549$71.84B
Q1 202547$53.14B
Q4 202440$38.79B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 381 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BSX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 20, 2026Analysis-
8-KNov 17, 2026Analysis-
4Nov 6, 2026--
4Nov 3, 2026--
10-QNov 2, 2026Analysis
8-KOct 28, 2026Analysis-
8-KOct 7, 2026Analysis-
8-KSep 23, 2026Analysis-
8-KSep 8, 2026Analysis-
4Sep 3, 2026--
8-KAug 26, 2026Analysis-
4Aug 26, 2026--
4Aug 12, 2026--
4Aug 11, 2026--
4Aug 7, 2026--
4Aug 5, 2026--
4Aug 5, 2026--
4Aug 3, 2026--
4Aug 3, 2026--
10-QAug 3, 2026Analysis
8-KJul 29, 2026Analysis-
8-KJul 27, 2026Analysis-
4Jul 2, 2026--
4Jun 1, 2026-
4May 21, 2026-

Related Health Care companies

All Health Care →

BSX SEC filings: frequently asked questions

Are BSX insiders buying or selling?

In the last 90 days, Boston Scientific (BSX) officers, directors and 10% owners reported 1 open-market purchase worth $100,408 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BSX stock?

As of September 30, 2026, the largest Boston Scientific (BSX) holders among the 13F filers tracked by SignalX were BlackRock ($5.5 billion), Vanguard Capital Management LLC ($4.1 billion), State Street Corp ($2.9 billion), Vanguard Portfolio Management LLC ($2.0 billion), Franklin Resources ($1.2 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BSX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Boston Scientific (BSX) reported revenue of $20.1 billion (up 19.9% from FY2024) and net income of $2.9 billion. Diluted EPS was $1.94. The figures come from the XBRL data in the 10-K.

What are the main risks in BSX's latest 10-K?

In the 10-K filed February 17, 2026, Boston Scientific (BSX) flagged: Leverage ratio maximum 4.50x as of December 31, 2025, up from 3.75x pre-Axonics acquisition in November 2024. Total debt $11.436B at end of 2025, up from $10.746B in 2024, fixed-rate debt $11.393B versus variable $43M. (AI summary of the Risk Factors section.)

What did BSX report in its latest 8-K?

Boston Scientific (BSX) filed an 8-K on November 20, 2026 reporting Item 8.01 (Other Events) and Item 1.01 (Entry into a Material Definitive Agreement). November 19, 2026 press release announces the material event described in the 8-K.

What are the latest BSX SEC filings?

Boston Scientific (BSX) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 2, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 6, 2026.

What is BSX's SEC CIK number?

Boston Scientific (BSX)'s SEC Central Index Key (CIK) is 885725. EDGAR lists every BSX filing under that number.

Ask anything about BSX

The research agent reads BSX's filings, financials, insider trades and 13F holders, then answers with sources.